BioLine Rx Analyst Price Targets - Benzinga

BioLine Rx Ltd

BLRXNASDAQ

Trade with Public

Trade with Public

$2.26

0.052.26%

最終更新: Oct 9, 10:07 AM

$2.28

0.073.17%

概要ニュース業績予想イベント目標株価財務センチメント比較オプション株式レポート

BioLine Rx Analyst Price Targets - Benzinga

BioLine Rx Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioLine Rx (BLRX).

Price Target Range — 7 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$19Upside to Avg. PT+740.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 17, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$26
May 30, 2025	Jones Trading	Justin Walsh	Upgrade	Hold→Buy	$12
May 28, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$26
Apr 2, 2025	Jones Trading	Justin Walsh	Downgrade	Buy→Hold	—
Mar 31, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$9→$26
Nov 25, 2024	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$21→$9
Nov 6, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Sep 4, 2024	Jones Trading	Justin Walsh	Initiate	Buy	$2
Jun 3, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
May 29, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Apr 17, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Mar 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Feb 29, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
Nov 20, 2023	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21

More with Benzinga EdgeGet Access

Analyst Ratings News

Where BioLine Rx Stands With Analysts

Benzinga Insights

PRO
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Jones Trading Upgrades BioLine Rx to Buy, Announces $12 Price Target

Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:BLRX) from Hold to Buy and announces $12 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Jones Trading Downgrades BioLine Rx to Hold

Jones Trading analyst Justin Walsh downgrades BioLine Rx (NASDAQ:BLRX) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $26

HC Wainwright & Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $9 to $26.

Benzinga Newsdesk